
FDA Approves New Teva Schizophrenia Treatment — Stock Jumps
Teva received approval from the U.S. Food and Drug Administration to market WELTRUZA, intended for adults • The new treatment is based on the active ingredient olanzapine and is administered as a once-monthly subcutaneous injection without the need for loading doses • The drug is expected to be available in the United States in the coming weeks